In this article we discuss the challenges for manufacturers of therapeutics and diagnostics as they pursue the potential of companion diagnostics. Click below to read the article.
Impact of CT outcomes on time to market and list price of orphan medicines in France
More innovative medicines have a shorter assessment time by the CT ASMR rating achieved vs. average time from EMA approval to outcome of CT assessment Key...